The new drug project of Changchun Baike biology and mucosis B.V. in the Netherlands is undergoing technology transfer
-
Last Update: 2015-03-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In 2014, bacco biology signed a relevant agreement with the Dutch company mucosis B.V., which invested 3.5 million euros in two phases to subscribe for mucosis B.V 25% of the company At the same time, mucosis B.V The company and bacco bio are the new respiratory syncytial virus vaccine (syngem ○ R) and mimopath from mucosis B.V of the Netherlands Technology is authorized Changchun hi tech takes biopharmaceutical, Chinese patent medicine production and sales, real estate development as the leading industries, supplemented by infrastructure construction and property management in the development zone.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
